Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors-A Narrative Review.
CART
immunotherapy
radiotherapy
solid tumor
tumor microenvironment
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
14 Aug 2023
14 Aug 2023
Historique:
received:
29
06
2023
revised:
04
08
2023
accepted:
09
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Tumor behavior is determined by its interaction with the tumor microenvironment (TME). Chimeric antigen receptor (CART) cell therapy represents a new form of cellular immunotherapy (IT). Immune cells present a different sensitivity to radiation therapy (RT). RT can affect tumor cells both modifying the TME and inducing DNA damage, with different effects depending on the low and high doses delivered, and can favor the expression of CART cells. CART cells are patients' T cells genetically engineered to recognize surface structure and to eradicate cancer cells. High-dose radiation therapy (HDRT, >10-20 Gy/fractions) converts immunologically "cold" tumors into "hot" ones by inducing necrosis and massive inflammation and death. LDRT (low-dose radiation therapy, >5-10 Gy/fractions) increases the expansion of CART cells and leads to non-immunogenetic death. An innovative approach, defined as the LATTICE technique, combines a high dose in higher FDG- uptake areas and a low dose to the tumor periphery. The association of RT and immune checkpoint inhibitors increases tumor immunogenicity and immune response both in irradiated and non-irradiated sites. The aim of this narrative review is to clarify the knowledge, to date, on CART cell therapy and its possible association with radiation therapy in solid tumors.
Identifiants
pubmed: 37623511
pii: jpm13081261
doi: 10.3390/jpm13081261
pmc: PMC10455986
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Biomedicines. 2022 Mar 11;10(3):
pubmed: 35327456
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Clin Cancer Res. 2021 May 1;27(9):2470-2480
pubmed: 33568343
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
J Biomed Biotechnol. 2010;2010:956304
pubmed: 20467460
Oncoimmunology. 2022 Dec 22;12(1):2158013
pubmed: 36567802
Mol Ther. 2018 Nov 7;26(11):2542-2552
pubmed: 30415658
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Front Oncol. 2023 May 25;13:1202093
pubmed: 37305566
JAMA Oncol. 2017 Aug 01;3(8):1094-1101
pubmed: 28426845
Crit Care Med. 2017 Feb;45(2):e124-e131
pubmed: 27632680
Trends Cancer. 2017 Nov;3(11):797-808
pubmed: 29120755
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Cancer Immunol Res. 2013 Jul;1(1):26-31
pubmed: 24777247
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203
pubmed: 32036004
Radiol Med. 2022 Feb;127(2):214-219
pubmed: 35034325
Front Immunol. 2021 Mar 12;12:625667
pubmed: 33777008
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Cancers (Basel). 2020 Mar 13;12(3):
pubmed: 32183246
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33106386
Cancer Lett. 2021 Apr 1;502:84-96
pubmed: 33450360
Cancer J. 2014 Mar-Apr;20(2):119-22
pubmed: 24667956
Int J Mol Sci. 2021 Mar 01;22(5):
pubmed: 33804441
Expert Opin Biol Ther. 2015;15(8):1145-54
pubmed: 25985798
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92
pubmed: 9653127
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575
pubmed: 29383033
Expert Opin Biol Ther. 2020 Jun;20(6):653-664
pubmed: 32067497
Front Immunol. 2022 Nov 17;13:1033512
pubmed: 36466874
Annu Rev Immunol. 2003;21:807-39
pubmed: 12615893
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56
pubmed: 20304086
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Biomed Pharmacother. 2021 Jul;139:111607
pubmed: 33965730
Exp Ther Med. 2021 Jan;21(1):96
pubmed: 33363607
Science. 2004 Jul 9;305(5681):200-5
pubmed: 15247469
J Clin Invest. 2019 Dec 2;129(12):5077-5078
pubmed: 31638599
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34615704
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34209192
Front Immunol. 2019 Jul 03;10:1462
pubmed: 31333642
Cell Rep Med. 2021 Apr 09;2(4):100227
pubmed: 33948568
JAMA Oncol. 2021 Jul 01;7(7):1051-1059
pubmed: 33885725
Radiother Oncol. 2022 Aug;173:299-305
pubmed: 35772575
Phys Med. 2019 Aug;64:145-156
pubmed: 31515013
Front Oncol. 2021 Feb 12;10:548132
pubmed: 33643893
Int J Mol Sci. 2018 Dec 09;19(12):
pubmed: 30544863
Cell Oncol (Dordr). 2021 Aug;44(4):715-737
pubmed: 33835425
Front Immunol. 2022 Mar 03;13:835762
pubmed: 35309357
Neoplasia. 1999 Jun;1(2):123-7
pubmed: 10933046
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052261
Eur Arch Otorhinolaryngol. 2019 May;276(5):1465-1473
pubmed: 30815724
Blood Adv. 2020 Feb 25;4(4):676-686
pubmed: 32084260
Gene. 2001 Apr 18;267(2):173-82
pubmed: 11313144
Int Rev Cell Mol Biol. 2022;370:123-147
pubmed: 35798503
JAMA Oncol. 2015 Dec;1(9):1325-32
pubmed: 26270858
Radiother Oncol. 2011 Jul;100(1):22-32
pubmed: 21511351
Immunol Rev. 2014 Jan;257(1):72-82
pubmed: 24329790
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Nat Rev Immunol. 2022 Feb;22(2):85-96
pubmed: 34002066
Sci Rep. 2015 Oct 30;5:15809
pubmed: 26515758
Adv Radiat Oncol. 2021 Jan 08;6(3):100639
pubmed: 34195486
Genome Med. 2019 Jun 20;11(1):40
pubmed: 31221199
Blood. 2000 Sep 1;96(5):1999-2001
pubmed: 10961908
Blood. 2013 Jun 27;121(26):5154-7
pubmed: 23678006
In Vivo. 2021 May-Jun;35(3):1507-1513
pubmed: 33910828
J Leukoc Biol. 2010 Sep;88(3):463-73
pubmed: 20501749
Cancers (Basel). 2022 Aug 12;14(16):
pubmed: 36010902
J Exp Clin Cancer Res. 2020 May 18;39(1):89
pubmed: 32423420
Cureus. 2015 Nov 24;7(11):e389
pubmed: 26719832
Int J Cancer. 2020 Sep 15;147(6):1509-1518
pubmed: 31997345
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Radiat Res. 2020 Dec 1;194(6):737-746
pubmed: 33064814
Biology (Basel). 2022 Jun 18;11(6):
pubmed: 35741450
Br J Haematol. 2018 Jun;181(5):689-692
pubmed: 28369673
Front Immunol. 2020 Mar 05;11:176
pubmed: 32194541
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Front Immunol. 2020 Jun 17;11:1109
pubmed: 32625204
N Engl J Med. 2012 Dec 20;367(25):2385-95
pubmed: 23252525
Sci Rep. 2017 Jan 20;7:39833
pubmed: 28106050
Radiat Res. 2023 Feb 1;199(2):161-169
pubmed: 36580642
Sci Rep. 2017 Feb 16;7:42396
pubmed: 28205588
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Expert Rev Clin Immunol. 2009 Sep;5(5):499-521
pubmed: 20477639
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32912922
Oncogenesis. 2018 Jan 24;7(1):10
pubmed: 29362402
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Immunity. 2006 Sep;25(3):455-71
pubmed: 16973386
J Exp Med. 1992 Nov 1;176(5):1453-7
pubmed: 1402688
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34301811
Lancet Oncol. 2020 Mar;21(3):e168-e178
pubmed: 32135120
Cancer Res. 2010 Feb 15;70(4):1534-43
pubmed: 20145121
J Immunol. 2006 Nov 1;177(9):6548-59
pubmed: 17056587
Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166746
pubmed: 37160171
Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):502-514
pubmed: 34023423
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Signal Transduct Target Ther. 2021 Apr 23;6(1):153
pubmed: 33888679
Lancet Oncol. 2022 Feb;23(2):279-291
pubmed: 35033226
Trends Endocrinol Metab. 2012 Nov;23(11):560-6
pubmed: 22824010
Leukemia. 2021 Mar;35(3):823-834
pubmed: 32632096
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):389-400
pubmed: 28068246
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36549782
Oncoimmunology. 2017 Nov 27;7(3):e1395996
pubmed: 29399393
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
Mol Ther Oncolytics. 2018 Aug 28;11:20-38
pubmed: 30306125
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Dis Model Mech. 2015 Apr;8(4):337-50
pubmed: 26035842
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Mol Ther. 2017 May 3;25(5):1234-1247
pubmed: 28341563
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
J Thorac Dis. 2014 Apr;6(4):287-302
pubmed: 24688774
J Neurooncol. 2023 Jan;161(2):203-214
pubmed: 35927392
Am J Med Sci. 2013 Aug;346(2):123-7
pubmed: 23255243
Immunotherapy. 2015;7(9):967-980
pubmed: 26310908